Bevacizumab biosimilar (MB02) and reference bevacizumab in patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC) (STELLA study): Multiple Imputation analysis.

Results

Title:	Bevacizumab biosimilar (MB02) and reference bevacizumab in patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC) (STELLA study): Multiple Imputation analysis.
Authors:	Trukhin, Dmytro; Poddubskaya, Elena; Andric, Zoran G ; Bondarenko, Igor N; Shevnia, Serhii; Zaric, Bojan ; Bellala, Ravishankar; Charoentum, Chaiyut; Perez, Luis; Bullo, Felicitas; Garcia, Fernanda;
Issue Date:	2021
Publication:	JOURNAL OF CLINICAL ONCOLOGY
ISSN:	0732-183X Journal of Clinical Oncology Search Idenfier
Type:	Conference Paper
Collation:	vol. 39 br. 15 str. e15003
DOI:	10.1200/JCO.2021.39.15_suppl.e15003
WoS-ID:	000708120301079
URI:	https://enauka.gov.rs/handle/123456789/802342
Project:	mAbxience Research
Metadata source:	(Preuzeto iz Nasi u WoS)
Note:	Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, JUN 04-08, 2021
M-category:	Mp. category will be shown later

Altmetric

Dimensions

Unpaywall

Google Scholar^TM